United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Gilead Sciences

GlaxoSmithKline

Healthcare is one of the most defensive sectors and often contains strong moats. Fortunately for income investors, there are also numerous high-yield opportunities in the space.

4 High-Yield Healthcare Stocks That Could Richly Reward Investors

Pfizer and its German partner BioNTech's Covid-19 shot has emerged as one of the most sought-after vaccines. Below are some of the recent updates relating to the shot.

New Developments For Covid-19 Shot Bode Well For Pfizer Stock

Pfizer projects approximately $15 to $20 billion in 2021 revenue from the vaccine. Investors appear to view the spike in vaccine revenue as a one-time event.

Pfizer: Why It's An Easy High Conviction Buy

Pfizer owns one of the best COVID vaccines that will boost its revenues by quite a lot in 2021, but there is more to like beyond that.

Pfizer: COVID Vaccine And Beyond

The leading developers of mRNA drugs hope the claim turns out to be foolish.

Pfizer's CEO Makes a Claim That Might Shock Anyone Holding Moderna or BioNTech Stock

BioNTech SE

Look for sales of the vaccine to be better than expected, too.

Why Pfizer and BioNTech's COVID Vaccine Could Be Even Better Than Expected

Pfizer Offers Investors An 18% To 100% Return

Pfizer Inc (NYSE: PFE) is reportedly working on a new COVID-19 vaccine supply deal to Israel after an initial agreement announced in late 2020 has ended. “The company is currently working with the Israeli government to update the agreement, to supply additional vaccines to the country.

Pfizer In Talks With Israel For New COVID-19 Vaccine Supply Deal: Reuters

The country says it hopes to vaccinate teenagers soon, and will likely need doses to provide booster shots.

Pfizer Negotiating Deal to Sell More Covid-19 Vaccine to Israel

Pharmaceutical giant Pfizer and its German partner BioNTech have earned much news lately due to their successful warp speed COVID-19 vaccine development. This article updates my 2016 article on the PFE holding I initiated in 2001.

Pharmaceutical Company Pfizer Dividend Growth Investing Results

In a post-pandemic world, one company has the lower valuation and higher dividend yield to be a success.

Better Buy for 2021: Pfizer or Gilead?

Johnson & Johnson

Merck

Do the math before you sell stocks based on proposed legislation.

How the Infrastructure Bill Will Raise Taxes on 3 Big Pharma Stocks

Moderna

They're working to target coronavirus strains of the future.

These 3 Vaccine Stocks May Be Post-Pandemic Winners

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of a presentation and conference call with investment analysts at 10 a.m. EDT on Friday, April 9, 2021. Pfizer Oncology leadership will provide an update on the Oncology pipeline progress, specifically how the company is applying its capabilities to move quickly and utilize cutting-edge science to key programs such as LORBRENA® (lorlatinib) in ALK-positive metastatic lung c

Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Review Oncology Business on April 9, 2021

TCG BDC

Canadian Natural Resources

Enbridge

Lockheed Martin

Medical Properties Trust

Realty Income Corp

OFS Capital

Sometimes, it may seem like growth and momentum investing is the way to go, but in the long run, a focus on value and income stocks is a winning strategy. Not all income stocks are necessarily attractive at a certain point - one should consider valuation before making an investment.

Top 10 Undervalued High-Yield Income Stocks For Q2

Top-line results from clinical trials also show the jab protects against the so-called South African variant.

Pfizer and BioNTech's Coronavirus Vaccine Remains Effective for at Least 6 Months

Danaher

Amplify Treatments Testing & Advancements ETF

Hologic

Immunovant Inc

Health Care Select Sector SPDR Fund

Covid-19 has put healthcare stocks in the limelight. These seven companies should be on your radar for the next pandemic.

7 Healthcare Stocks to Buy to Prepare Your Portfolio For The Next Pandemic

According to real-world data in the U.K., around 98% of elderly aged between 80 to 96 years who received two doses of Pfizer Inc's (NYSE: PFE) coronavirus vaccine had a strong antibody immune response, reports Reuters. A study of 100 older adults in Britain also found that vaccinated participants already had a peak antibody response after just one dose of the vaccine, and this response remained high after their second dose.

UK Data Shows Substantial Immune Response With Pfizer COVID-19 Shot In Elderly

In a joint statement on Thursday, Pfizer Inc (NYSE: PFE) and BioNTech (NASDAQ: BNTX) said new data showed their Coronavirus vaccine had an efficacy of over 91% after six months. Initially, in November, the two companies had published data from their late-stage clinical trial that included 44 thousand participants, in which the vaccine was shown […] The post Updated data shows Pfizer/BioNTech COVID-19 vaccine to be 91% effective appeared first on Invezz.

Updated data shows Pfizer/BioNTech COVID-19 vaccine to be 91% effective

Findings based on two doses three weeks apart are first to show shot remains effective for many months

Pfizer vaccine has 91% efficacy for up to six months, trial shows

There was welcome news on the COVID-19 vaccine front Thursday, as Pfizer Inc. and German partner BioNTech SE said a follow-up study of their vaccine found it remained safe and highly effective six months after a second dose.

Coronavirus Update: Pfizer and BioNTech say their COVID-19 vaccine is safe and highly effective — including against South Africa variant

BioNTech stock continued a sprint Thursday after the company suggested its Pfizer-partnered Covid vaccine is effective against a mutation first identified in South Africa. The post Pfizer Suggests Covid Vaccine Can Tackle South Africa Variant; BioNTech Pops appeared first on Investor's Business Daily.

Pfizer Suggests Covid Vaccine Can Tackle South Africa Variant; BioNTech Pops

The shares of Pfizer Inc. (NYSE:PFE) are down 0.2% at $36.15 at last check, despite the drug maker posting updated results that showed its Covid-19 vaccine, in partnership with BioNTech (BNTX), is 91% effective for up to six months.

Pfizer Stock Dips Despite Upbeat Covid-19 Vaccine Data

Pfizer may be on its way to vaccinating another group.

Did Pfizer Just Leap Ahead of Moderna in This Key Market?

The vaccine has been okayed for emergency use in the U.S. for people aged 16 or older.

News for Pfizer Stock (PFE)